In 2023, the import of ephedrines to the US stood at a certain value which marked the end of the actual data and the beginning of forecasted values in 2024. The forecast indicates a year-on-year decrease in the import value by approximately 15% from 2024 to 2025, around 17% from 2025 to 2026, 20% from 2026 to 2027, and about 25% from 2027 to 2028. The compound annual growth rate (CAGR) over the period from 2024 to 2028 projects a notable average annual decline.
Future trends to watch for include potential regulatory changes impacting import requirements, shifts in demand for ephedrines in the pharmaceutical industry, and any advancements in synthetic alternatives that might further reduce imports. Monitoring these factors can provide insights into the accuracy and adjustments needed for future forecasts.
